Senseonics to Present Real-World, Long-Term Safety Data of the First Implantable CGM Sensor at the American Diabetes Association’s 79th Scientific Sessions
Summary
GERMANTOWN, MD--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, will present the long-term safety data of the Eversense CGM System derived from its Post Market Clinical Follow Up (PMCF) registry in Europe. The poster is to be presented by Katherine Tweden, PhD on Saturday, June 8 from 11:30 am – 12:30 pm in Hall F of the North Exhibition building during the annual American Diabetes Association Scientific Sessions held in San Francisco. The purpose of the prospective PMCF registry was to establish the long-term safety of the Eversense CGM System after repeated insertions in real-world home-use settings. Repeat insertions of the Eversense CGM confirmed the safety profile of prior studies and showed it to be safe for long-term continuous use. The Eversense CGM System is a prescription device; patients should talk to their health care provider to learn more.